Sumitomo Chemical India Limited — Q4 FY25 earnings call

Call held 28 May 2025

Management summary

Sumitomo Chemical India delivered a record-breaking FY25, characterized by strong volume-led growth that successfully offset significant pricing pressures. While Q4 faced temporary headwinds in the export market (specifically LATAM) and shipment timing issues, the company achieved its highest-ever annual margins and PAT. Management is pivoting aggressively toward high-margin patented molecules and has committed to a multi-site Capex plan to support both domestic demand and global supply for its parent company.

Highlights

  • Record annual profitability with FY25 PAT at ₹506 crore, up 37% YoY.

  • Full-year revenue reached ₹3,149 crore, an 11% increase despite a 10% pricing headwind.

  • Volume growth was robust: 20% in the domestic branded business and 30%+ in exports for FY25.

  • EBITDA margins expanded by 339 bps YoY to 20.1% for the full year, the highest in company history.

  • Announced ₹365 crore+ in strategic Capex across Bhavnagar (₹55cr), Tarapur (<₹10cr), and Dahej (₹300cr).

  • Launched two high-potential patented molecules from parent SCC: Excalia Max (fungicide) and Lentigo (herbicide).

  • Q4 FY25 revenue was flat at ₹679 crore (+1% YoY) with EBITDA margins contracting to 17.6% due to LATAM headwinds.

Key financials

  1. Revenue ₹3,149 Cr +11%YoY
  2. EBITDA Margin 20.1%
  3. PAT ₹506 Cr +37%YoY
  4. Gross Margin 41%

What they filed

Q1 FY27: revenue up 0.6%, net profit up 20.8% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue988 642 679 1,057 930 −6%568 −12%684 +1%1,063 +1%
EBITDA245 106 120 219 218 −11%99 −7%134 +12%233 +6%
Net profit193 87 100 178 178 −8%76 −13%111 +11%215 +21%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

SegmentRevenue ContributionRevenue GrowthVolume Growth
Domestic Agro-chemical78%8%20%
Exports22%22%30%

Guidance & targets

Capex

  • Bhavnagar Brownfield Investment Capex · Q4 FY27 · High confidence ₹55 crore
    With the further investment of about INR 55 crore, and with this we are targeting to double the capacities... This plant is expected to be completed by Q4 Financial Year 2026-27.

    — Kunal Mittal, Senior Vice President

  • Tarapur Brownfield Investment Capex · Q4 FY27 · High confidence <₹10 crore
    The estimated CAPEX for this project is less than Rs. 10 crore... expected to be completed by Financial Year '26-'27, Q4.

    — Kunal Mittal, Senior Vice President

  • Dahej Greenfield Initial Investment Capex · 2027-2030 · Medium confidence ₹300 crore
    We plan to invest, as informed earlier, an initial investment of Rs. 300 crore to start with... we want to start manufacturing certain products to deliver between '27, '28, '29 and '30.

    — Chetan Shah, Managing Director

Volume

  • Kharif Food Grain Output Target Volume · FY26 · Medium confidence 1.5%
    a targeted 1.5% year-on-year increase in Kharif food grain output for Financial Year '26.

    — Chetan Shah, Managing Director

Market context

  • Global Supply Share for SCC Molecule Capacity · Post-FY27 · Medium confidence 40-50%
    SCIL will be able to meet 40% to 50% of the global requirement.

    — Kunal Mittal, Senior Vice President

Risks & concerns

  • Pricing Headwinds and Realization Pressure

    medium

    Management noted a 10% price drop across domestic and export markets in FY25, though they believe prices have now bottomed out.

    Management acknowledged

  • LATAM Market Volatility

    medium

    Export volumes were hit in Q4 due to headwinds in Latin America, although full-year growth remained strong.

    Both acknowledged

  • Registration Delays for Export Molecules

    low

    Delays in global registrations for certain ESD products at the Tarapur plant have pushed back some project timelines.

    Management acknowledged

Areas of evasion (2)

  • Specific revenue targets for new molecules
  • Detailed margin breakdown between domestic and export segments

Q&A highlights

2 direct, 1 evasive
Revenue expectations from new molecules (Excalia Max and Lentigo) Evasive
Our aspiration is big, but we can't commit any number at this point of time.

Investors are looking for the scale of these 'blockbuster' launches to model future growth, but management is being conservative.

Asked by Bhavya Gandhi, Dalal and Broacha

Q4 Margin and Profit Dip Direct
In Quarter 4... our volume got hit on account of two. One, the price dropped... And also volume has taken a slight hit in terms of Quarter 4 compared to the previous year in exports.

Explains the disconnect between a strong domestic Rabi season and the weaker-than-expected Q4 consolidated results.

Asked by S. Ramesh, Nirmal Bang Equities

EBITDA Margin Ceiling Direct
I think that ceiling which we had in our mind, that margins more than 20%... I think we are behind that. And we have realized that in this year also... we have delivered EBITDA margins which are higher than 20%.

Management is signaling a structural shift in profitability expectations, moving past their previous 20% margin guidance.

Asked by Ankur Periwal, Axis Capital

2 min read 5 chapters

Detailed narrative

Record Annual Profitability Amidst Pricing Headwinds

Sumitomo Chemical India achieved its highest-ever annual profitability in FY25, with PAT growing 37% to ₹506 crore. This was driven by a significant 339 bps expansion in EBITDA margins to 20.1%. The growth was primarily volume-led, with domestic branded volumes up 20% and export volumes up over 30%, which more than compensated for a 10% decline in realizations across the board.

Strategic Pivot to High-Margin Patented Molecules

The company is transitioning its portfolio toward higher-margin specialty products. Key launches include Excalia Max (INDIFLIN) and Lentigo, both patented molecules from parent SCC. Management expects Excalia Max to be a 'blockbuster' and plans to begin technical manufacturing in India within 12-15 months at the Tarapur facility to meet domestic demand and eventually support global requirements.

Multi-Pronged Capex Strategy

Management announced a comprehensive Capex plan involving three sites. A ₹55 crore investment at Bhavnagar will double capacity for a proprietary SCC molecule by Q4 FY27. A smaller <₹10 crore investment at Tarapur will establish a line for Excalia Max. Finally, a ₹300 crore initial investment is planned for a Greenfield site at Dahej, with phased commercialization expected between 2027 and 2030.

Export Resilience and Geographical Diversification

Despite a sluggish Q4 in the LATAM market, full-year export revenue surged 22%. Sales to South America and North America increased by 78% and 44% respectively for the full year. The company is actively diversifying its export footprint into Africa and Asia to balance regional risks and capitalize on emerging opportunities.

Operational Efficiency and Margin Expansion

The record margins in FY25 were attributed to a superior product mix, strategic sourcing, and the proactive liquidation of high-cost inventory. Management signaled that the previous 20% EBITDA margin 'ceiling' is no longer a constraint, as they focus on high-margin demand generation rather than just top-line growth, suggesting a structural improvement in the company's earnings profile.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls